Survival of skin allografts is prolonged in mice with a dominant-negative H-Ras.

[1]  L. Turka,et al.  Defective Activation of Protein Kinase C and Ras-ERK Pathways Limits IL-2 Production and Proliferation by CD4+CD25+ Regulatory T Cells1 , 2006, The Journal of Immunology.

[2]  L. Puente,et al.  A novel PKC regulates ERK activation and degranulation of cytotoxic T lymphocytes: Plasticity in PKC regulation of ERK , 2006, European journal of immunology.

[3]  S. Ng,et al.  Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  Xiao‐Kang Li,et al.  Inhibition of allogeneic T‐cell responses by dendritic cells expressing transduced indoleamine 2,3‐dioxygenase , 2005, The journal of gene medicine.

[5]  C. June,et al.  CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. , 2004, Blood.

[6]  J. Hancock,et al.  Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.

[7]  D. Cantrell.  GTPases and T cell activation , 2003, Immunological reviews.

[8]  D. Theodorescu,et al.  Ras superfamily monomeric G proteins in carcinoma cell motility. , 2003, Cancer letters.

[9]  V. Lafont,et al.  Evidence for a p21 ras /Raf-1/MEK-1/ERK-2-independent Pathway in Stimulation of IL-2 Gene Transcription in Human Primary T Lymphocytes* , 1999, The Journal of Biological Chemistry.

[10]  R. Perlmutter,et al.  T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Puente,et al.  Sustained TCR signaling is required for mitogen-activated protein kinase activation and degranulation by cytotoxic T lymphocytes. , 1998, Journal of immunology.

[12]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[13]  P. Fields,et al.  Blocked Ras Activation in Anergic CD4+ T Cells , 1996, Science.

[14]  A. Mondino,et al.  Blocked Signal Transduction to the ERK and JNK Protein Kinases in Anergic CD4+ T Cells , 1996, Science.

[15]  R. Perlmutter,et al.  Involvement of p21ras distinguishes positive and negative selection in thymocytes. , 1995, The EMBO journal.

[16]  L. Williams,et al.  The post-translational modification of ras p21 is important for Raf-1 activation. , 1994, The Journal of biological chemistry.

[17]  D. Cantrell,et al.  p21ras and calcineurin synergize to regulate the nuclear factor of activated T cells , 1993, The Journal of experimental medicine.

[18]  A. Jaramillo,et al.  Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation , 1993, The Journal of experimental medicine.

[19]  J. Downward,et al.  p21ras mediates control of IL‐2 gene promoter function in T cell activation. , 1992, The EMBO journal.

[20]  K. Brorson,et al.  Transactivation by AP-1 Is a Molecular Target of T Cell Clonal Anergy , 1992, Science.

[21]  P. Warne,et al.  Stimulation of p21ras upon T-cell activation , 1990, Nature.

[22]  M. Miyamoto,et al.  Male skin isografts can induce unresponsiveness in female rats. , 1980, Transplantation.

[23]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.